Follows people with Parkinson's disease after advanced second-line treatments
Follows Parkinson's patients for 3 years after deep brain stimulation or drug pumps.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- Strasbourg, FranceSee the site
- Trial code
- Registry title
- Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)
- Status
- Not yet recruiting
- People taking part
- 150 people, planned
- Started
- Feb 2022
- Expected to end
- Mar 2028
- Type of study
- Observational
- Record updated
- 17 February 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Parkinson's disease who have motor fluctuations or dyskinesia and need a second-line treatment: deep brain stimulation, apomorphin pump or duodopa pump.
- Age
- Over 21 years (minimum age 21 Years).
- Sex
- All sexes can join.
- Disease stage
- Parkinson's disease (UKPDSSB criteria) with fluctuations and/or dyskinesia that need deep brain stimulation, apomorphin pump or duodopa pump.
- Biomarker or test result
- MOCA score above 20.
Main reasons for not taking part
- Another parkinsonian syndrome than Parkinson's disease
- MOCA score below 20
- Does not need a second-line treatment
- Did not give acceptance for the protocol
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Parkinson disease (UKPDSSB criteria)
- Patient with fluctuations and/or dyskinesia , who need treatment with deep brain stimulation, apomorphin pump or duodopa pump
- MOCA >20
- patient >21 years of age
- patient who has signed protocol acceptation
Who cannot take part
- patient with another parkinsonian syndrome than Parkinson' s disease
- patient who did not give his acceptation for the protocol
- MOCA<20
- Patient who does not need second line treatment
Where in France
- Mathieu ANHEIMStrasbourg, FranceContact: Mathieu ANHEIMNo longer taking part
About the trial
What the trial wants to find out
Primary purpose: Fluctuations and dyskinesia evolution in Parkinson's disease patients, one year after initiation of deep brain stimulation, apomorphin pump or duodopa pump
Read full original descriptionShow less
Secundary purposes:
* Motor complications evolution at 6 months, 2 and 3 years * MDS UPDRS III score at 6 months, 1, 2 and 3 years * non motor complications evolution at 6 months, 1, 2 and 3 years * cognition and psychiatric complications evolution at 6 months, 1, 2 and 3 years * cutaneous and digestive complications at 6 months, 1, 2 and 3 years * neuropathy occurrence at 6 months, 1, 2 and 3 years * medical treatment and Levodopa equivalent dose modifications at 6 months, 1, 2 and 3 years
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)
- Plain-language title
- Follows people with Parkinson's disease after advanced second-line treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 February 2022